Phase I study of weekly low dose Paclitaxel for pancreato-biliary cancers after failure of gemcitabine and 5-F
Phase 1
- Conditions
- pancreato-biliary cancers
- Registration Number
- JPRN-UMIN000008148
- Lead Sponsor
- Kanazawa University Hospital Hepato-Biliary-Pancreatic Surgery
- Brief Summary
BTC: PR 3, SD 2, PD 1 PDAC: SD 4, PD 6
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 16
Inclusion Criteria
Not provided
Exclusion Criteria
Patients with a history of anti-cancer agent taxane administration.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Determination of recommended dose
- Secondary Outcome Measures
Name Time Method Assessment of safety, Prolonged survival after failur of S-1 and GEM, Response rate, Disease control rate, Adverse event